Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): Case Definition in Surveillance for Childhood-Onset Duchenne/Becker Muscular Dystrophy

Abstract

The Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet) is a multisite collaboration to determine the prevalence of childhood-onset Duchenne/Becker muscular dystrophy and to characterize health care and health outcomes in this population. MD STARnet uses medical record abstraction to identify patients with Duchenne/Becker muscular dystrophy born January 1, 1982 or later who resided in 1 of the participating sites. Critical diagnostic elements of each abstracted record are reviewed independently by >4 clinicians and assigned to 1 of 6 case definition categories (definite, probable, possible, asymptomatic, female, not Duchenne/Becker muscular dystrophy) by consensus. As of November 2009, 815 potential cases were reviewed. Of the cases included in analysis, 674 (82%) were either ‘‘definite’’ or ‘‘probable’’ Duchenne/Becker muscular dystrophy. These data reflect a change in diagnostic testing, as case assignment based on genetic testing increased from 67% in the oldest cohort (born 1982-1987) to 94% in the cohort born 2004 to 2009.

Keywords

Duchenne muscular dystrophy Becker muscular dystrophy diagnostic testing dystrophin

Get full access to this article

View all access options for this article.

References

Koenig M. , Hoffman EP , Bertelson CJ , et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50:509-517.

Koenig M. , Monaco AP , Kunkel LM The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein . Cell. 1988;53:219-228.

Bonilla E. , Samitt CE , Miranda AF , et al. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell. 1988;54:447-452.

Miller LA , Romitti PA , Cunniff C. , et al. The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology. Birth Defects Res A Clin Mol Teratol. 2006;76:793-797.

Schwartz M. , Hertz JM , Sveen ML , Vissing J. LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. Neurology. 2005;64:1635-1637.

Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years-four states, 2007. MMWR Morb Mortal Wkly Rep . 2009;58:1119-1122.

Jennekens FG , ten Kate LP , de Visser M. , Wintzen AR Diagnostic criteria for Duchenne and Becker muscular dystrophy and myotonic dystrophy. Neuromuscul Disord . 1991;1:389-391.

Cunniff C. , Andrews J. , Meaney FJ , et al. Mutation analysis in a population-based cohort of boys with Duchenne or Becker muscular dystrophy. J Child Neurol. 2009;24:425-430.

Chamberlain JS , Gibbs RA , Ranier JE , et al. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res. 1988;16:11141-11156.

10.

Mendell JR , Buzin CH , Feng J. , et al. Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology. 2001;57:645-650.

11.

Dent KM , Dunn DM , von Niederhausern AC , et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A. 2005;134:295-298.

12.

Ciafaloni E. , Fox DJ , Pandya S. , et al. Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr. 2009;155:380-385.